Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2010
September 2010, Vol 1, No 4
September 2010, Vol 1, No 4
Comparative Effectiveness Research in Oncology Is High Priority
ASCO Conference
September 2010, Vol 1, No 4
Read Article
Cost-Effectiveness in the New Comparative Effectiveness Landscape
ASCO Conference
September 2010, Vol 1, No 4
Read Article
New Prostate Cancer Therapies Raise New Issues
By
Lee N. Newcomer, MD, MHA
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Prostate cancer patients have 2 new therapeutic options this summer with the approvals of sipuleucel-T and cabazitaxel. The former drug is an important scientific advance as one of the pioneering cancer vaccines to show a prolongation of survival.
Read Article
The $93,000 Question
By
Yu-Ning Wong, MD, MSCE
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Sipuleucel-T (Provenge) and cabazitaxel (Jevtana) have drawn much attention both for being the first new treatments for advanced prostate cancer since docetaxel (Taxotere) was approved in 2004, and for their high costs. As described in Dr Newcomer’s accompanying piece, they will add significantly to the cost of care for prostate cancer patients.
Read Article
Community Trials Essential to Broad Knowledge
By
Ed Pezalla, MD, MPH
Value-Based Care
,
VBCC Perspectives
September 2010, Vol 1, No 4
Several sessions at the recent ASCO meeting considered new standards for community-based oncology research and the development of comparative effectiveness research (CER) methods.
Read Article
New Compounds Hold Promise for Prostate Cancer
Prostate Cancer
,
Solid Tumors
September 2010, Vol 1, No 4
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease (CRPC). Docetaxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies.
Read Article
Comparing VHA with Fee-for-Service Cancer Care
By
Cherie Dewar
September 2010, Vol 1, No 4
Boston, MA—The work of 3 Harvard Medical School researchers presented at June’s AcademyHealth Conference provided a snapshot of how cancer care outcomes compare between the Veterans Health Administration (VHA) and the fee-for-service Medicare community.
Read Article
Does Robotic Surgery Make the Cut?
By
Robertson Paton
September 2010, Vol 1, No 4
Over the past decade, polarized opinion has abounded regarding robot-assisted laparoscopy. On one side, many of the surgeons who pioneered the use of the da Vinci surgical robot (Intuitive Surgical, Sunnyvale, CA) in Germany and the United States described it as “revolutionary,” heralding “a new era,” and creating a “paradigm shift.”
Read Article
Understanding the Preventive Services Rule Changes
Health Policy
,
Policies & Guidelines
September 2010, Vol 1, No 4
On July 14, 2010, the Departments of Treasury, Labor, and Health and Human Services issued interim final rules for group health plans and health insurance issuers to provide detail on how those entities are to cover the preventive services required under the Patient Protection and Affordable Care Act (PPACA).
Read Article
Trial Participation Hampered by Costs
ASCO Conference
September 2010, Vol 1, No 4
Cost-related factors are a chief reason for patients declining to participate in a clinical trial, a survey of 4 community oncology practices showed.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma